Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea

Zhang, Xuhao; Leeuwenkamp, O. R.; Oh, Kyu-Bin; Lee, Young Eun; Kim, Chul-Min

doi:10.1080/21645515.2017.1362513

Cited by 12 publications

(40 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of the studies (n = 10) compared the potential benefits of two newer versions of PCV, namely PCV-10 and PCV-13 [20,25,28,31,34,36,37,42,44,47]. Seven studies assessed the cost-effectiveness of PCV-7 [27,29,30,32,33,39,46], of which one study assessed its effectiveness in the context of typical and pandemic influenza seasons [30].…”

Section: Methodsmentioning

confidence: 99%

“…The included studies were conducted in 11 Asian countries, including China (n = 7) [26,30,32,33,35,41,48] Malaysia (n = 3) [34,42,44], Hong Kong (n = 3) [28,29,42] Korea (n = 2) [25,46], The Philippines (n = 2) [31,36],Taiwan (n = 2) [27,43], Japan (n = 3) [20,38,39], Thailand (n = 1) [47], Mongolia (n = 1) [45], Bhutan (n = 1) [37], and India (n = 1) [40] (Table 1). One study was a multiple country analysis, performed in Malaysia and Hong Kong [42].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

et al. 2020

View full text Add to dashboard Cite

Background: Evidence on costs and health benefits of pneumococcal conjugate vaccine (PCV) for children in Asian countries is limited but growing. As a region with a considerably high burden of pneumococcal disease, it is prominent to have a comprehensive overview on the cost-effectiveness of implementing and adopting a PCV vaccination program. Methods: We conducted a systematic review from Pubmed and Embase to identify economic evaluation studies of PCV for children in Asian countries up to May 2020. Data extraction included specific characteristics of the study, input parameters, cost elements, cost-effectiveness results, and key drivers of uncertainty. The Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement was followed for this systematic review. The reporting quality of the included studies was evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Results: After the screening process on both the title and abstract and full text of 518 records, a total of 25 studies fulfilled the inclusion criteria, and were included in the review. The majority of included studies demonstrates that PCV for children is cost-effective in most of the Asian region, and even cost-saving in some countries. Most of the included studies implemented cost utility analysis (CUA) using either quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). Overall, the main drivers affecting the cost effectiveness were vaccine price, burden regarding pneumonia-related parameters, and the inclusion of herd effects. Conclusion: The children pneumococcal vaccination program appears to be a cost-effective intervention in Asia, and even cost-saving in certain conditions. Vaccine price, pneumonia-related disease burden, and the inclusion of the herd effect are observed as important key drivers in estimating cost-effectiveness in this region. Incorporating PCV in vaccination programs in this region was found to be highly favorable.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…10 In May 2014, the first Korean pediatric pneumococcal NIP was implemented with a 3 + 1 schedule in infants and both PCV10 and PCV13 were included as a physician choice; however, 88.6% of infants are vaccinated with PCV13. 11 Although a recent cost-effectiveness study by Zhang et al estimated that PCV10 would be cost-saving compared to PCV13 in Korea, 12 it did not capture the full spectrum of health outcomes associated with introducing PCVs. Notably, Zhang et al did not account for population-level indirect effects in older age groups due to reductions in carriage circulation, therefore imply that both PCVs would induce the same herd protection and have no impact on the results.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea

Kim

Park

Kang

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Introduction: Globally, pneumococcal disease represents a significant burden. South Korea implemented the 7-valent pneumococcal conjugate vaccine (PCV7) in 2003, replaced with the 10-valent (PCV10) and 13valent (PCV13) vaccine in 2010. In 2014, both vaccines were introduced in the national immunization program (NIP) for infants with 3 primary doses and one booster dose We performed a cost-effectiveness evaluation to elucidate which vaccine may be expected to provide greater impact if included in a NIP. Methodology: Using an established model, we estimated the impact of introducing either PCV13 or PCV10 into the South Korean NIP in 2015. Vaccine impact was based on historic observed impact of PCV13 from 2010 to 2015 in Korea given high uptake of PCV13, and PCV10 impact was estimated based on experiences in countries using PCV10. Incidence and costs for all ages and including invasive pneumococcal disease, pneumonia, and acute otitis media were derived from the literature and Health Insurance Review and Assessment database. Results: In the base-case, over 5-years PCV13 was estimated to avert 550,000 more cases of pneumococcal disease compared to PCV10, driven by broader serotype coverage and less replacement due to serotypes 3 and 19A. This translated to a cost-savings of $47.4 million USD despite PCV13's higher cost. Sensitivity analysis found incremental cost-effectiveness ratios (ICERs) ranged from cost-saving to $7,300 USD per quality-adjusted life year (QALY). Conclusion: A NIP using PCV13 was estimated to have a more substantial public health impact and be cost-saving compared to a program with PCV10 due to broader serotype coverage.

show abstract

“…For example, a recent modeling exercise by the Joint Committee on Vaccination and Immunization categorized serotype 3 as an NVT in estimating the impact on removing a priming dose in infant vaccination [22]. Furthermore, a number of costeffectiveness studies also assume PCV13 provides no protection against serotype 3 [23][24][25]. If such an assumption is incorrect, it will underestimate the benefit of PCV13 vaccination.…”

Section: Introductionmentioning

confidence: 99%

Estimating the Vaccine Effectiveness Against Serotype 3 for the 13-Valent Pneumococcal Conjugate Vaccine: A Dynamic Modeling Approach

Lucas¹,

Wilson²,

Sings³

et al. 2019

IJIDT

View full text Add to dashboard Cite

Background: The 13-valent pneumococcal conjugate vaccine (PCV13) is the only PCV licensed to protect against serotype 3 in children. However, conflicting estimates exist of PCV13's direct and indirect protection vaccine effectiveness (VE) for serotype 3. Objective: Our study examined the of PCV13 for serotype 3 using different assumptions for PCV13 direct and indirect VE to model trends in serotype 3 invasive pneumococcal disease (IPD) and comparing these to observed data from the United Kingdom (UK). Methods: A dynamic transmission model of the spread of pneumococcal carriage and development of IPD was used to fit pre-PCV13-modeled IPD incidence with observed data. To allow for comparison across scenarios, post-PCV13-modeled IPD incidence was fit to observed data using assumptions for three different scenarios: (scenario 1) serotype 3 as a nonvaccine serotype, (scenario 2) VE against serotype 3 IPD of 63.5% based on a recent meta-analysis, and (scenario 3) a model-estimated VE against serotype 3. Results: Post-PCV13 introduction, modeled 2017 and average annual serotype 3 IPD incidence were within 20% and 59% of observed values for scenarios 2 and 3, respectively, but deviated by >100% for scenario 1. For adults aged ≥65 years, modeled 2017 IPD incidence in scenario 1 differed from observed data by 16% versus roughly 8% in scenarios 2 and 3. Conclusions: Observed data do not support a scenario of no serotype 3 VE, but rather a combination of direct protection among vaccinated children and a lower level of indirect protection among older adults. Policymakers should consider transmission dynamics when examining VE against covered serotypes.

show abstract

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea

Cited by 12 publications

References 48 publications

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea

Estimating the Vaccine Effectiveness Against Serotype 3 for the 13-Valent Pneumococcal Conjugate Vaccine: A Dynamic Modeling Approach

Contact Info

Product

Resources

About